Ads
related to: von willebrand function- Prophylaxis Information
Find prophylactic information
for this treatment option.
- Patient Support Page
Find information about a support
program for your patients.
- Stay Up-to-Date
Stay connected with the latest
updates about VONVENDI®.
- Dosing Guidelines
Find dosing guidelines
for 3 indications.
- Prophylaxis Information
Search results
Results from the WOW.Com Content Network
Von Willebrand factor (VWF) (German: [fɔn ˈvɪləbʁant]) is a blood glycoprotein that promotes primary hemostasis, specifically, platelet adhesion.It is deficient and/or defective in von Willebrand disease and is involved in many other diseases, including thrombotic thrombocytopenic purpura, Heyde's syndrome, and possibly hemolytic–uremic syndrome. [5]
Von Willebrand disease (VWD) is the most common hereditary blood-clotting disorder in humans. An acquired form can sometimes result from other medical conditions. [1] It arises from a deficiency in the quality or quantity of von Willebrand factor (VWF), a multimeric protein that is required for platelet adhesion. It is known to affect several ...
Von Willebrand factor type D domain (vWD) is an evolutionarily-conserved protein domain found in, among others, the von Willebrand factor (vWF). vWF is a large multimeric glycoprotein and it is synthesized by a type of bone marrow cell called megakaryocytes. The vWD domain allows vWF to perform its blood-clotting function by carrying factor ...
The von Willebrand factor type A (vWA) domain is a protein domain named after its occurrence in von Willebrand factor (vWF), a large multimeric glycoprotein found in blood plasma. Mutant forms of vWF are involved in the aetiology of bleeding disorders. [ 2 ]
Weibel–Palade bodies are the storage granules of endothelial cells, the cells that form the inner lining of the blood vessels and heart. [1] They manufacture, store and release two principal molecules, von Willebrand factor and P-selectin, and thus play a dual role in hemostasis and inflammation.
In 1957, it was discovered that von Willebrand disease is caused by a deficiency of a protein in blood plasma that enables hemostasis. [14] The protein was characterised in 1971, and is known as von Willebrand factor. [15] Von Willebrand factor has two functions. Firstly, it is the carrier molecule for factor VIII, the anti-hemophilic factor.
ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13)—also known as von Willebrand factor-cleaving protease (VWFCP)—is a zinc-containing metalloprotease enzyme that cleaves von Willebrand factor (vWf), a large protein involved in blood clotting.
The GPIbα subunit bears the binding site for von Willebrand factor (vWF), α-thrombin, leukocyte integrin αMβ2 and P-selectin. The binding between GPIbα and vWF mediates the capture of platelets to the injured vascular wall. The deficiency in glycoprotein Ib-IX-V complex synthesis leads to Bernard–Soulier syndrome. [1]
Ads
related to: von willebrand function